SCHEMBL4073364

SCHEMBL4073364

CCC(=O)N(Cc1ccncc1)Cc1cc2cc(C)cc(C)c2[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.56
KDM4E B2RXH2 7/20 0.56
HSD17B10 Q99714 4/20 0.56
HPGD P15428 4/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 2/20 0.52
POLB P06746 1/20 0.52
NPSR1 Q6W5P4 2/20 0.52
RECQL P46063 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GAA P10253 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GUSB P08236 4/20 0.50
HTT P42858 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5454251 0.87 MAPT (0.54) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL4081693 0.86 GUSB (0.60) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL4069789 0.82 ALDH1A1 (0.53) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL5448947 0.81 KDM4E (0.66) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL4251806 0.81 KDM4E (0.59) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL4069192 0.80 KDM4E (0.49) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL4247686 0.78 KDM4E (0.54) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL4077745 0.77 KDM4E (0.62) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL4081588 0.76 ALDH1A1 (0.65) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL23149480 0.76 GUSB (0.72) ALDH1A1KDM4EHSD17B10HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG ALDH1A1 1055/4885KDM4E 2403/4885HSD17B10 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.